Skip to content

Cellectar Biosciences, Inc.: 10-K filed 2017-03-15

What Cellectar Biosciences, Inc. reported in its annual report filed 2017-03-15 (fiscal FY 2016): 28 published measures, 58 facts as tagged in accession 0001144204-17-014611.

This filing

Form
10-K (annual report)
Filed
2017-03-15
Fiscal period
fiscal FY 2016
Accession
0001144204-17-014611 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Cellectar Biosciences, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2016-12-3115,324,580USD
At 2015-12-317,596,379USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2016-12-311,784,708USD
At 2015-12-315,946,576USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2016-12-3113,539,872USD
At 2015-12-311,649,803USD
At 2014-12-316,697,533USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2016-12-3111,444,619USD
At 2015-12-313,857,791USD
At 2014-12-319,422,627USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2016-01-01 to 2016-12-31-6,180,326USD366
2015-01-01 to 2015-12-31-5,495,030USD365

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2016-01-01 to 2016-12-3172,251USD366
2015-01-01 to 2015-12-3158,470USD365

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2016-12-31-70,787,026USD
At 2015-12-31-64,606,700USD

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2016-01-01 to 2016-12-310USD366
2015-01-01 to 2015-12-310USD365

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2016-12-311,444,058USD
At 2015-12-311,728,471USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2016-01-01 to 2016-12-31529,159USD366
2015-01-01 to 2015-12-31447,300USD365

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2016-01-01 to 2016-12-31-9,449,752USD366
2015-01-01 to 2015-12-31-8,757,865USD365

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2016-12-3112,193,188USD
At 2015-12-314,180,574USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2016-12-311,632,876USD
At 2015-12-315,703,045USD

Goodwill carrying amount

Recognized goodwill remaining after accumulated impairment. It arises from business combinations and does not measure the current value of the company’s brand.

PeriodValueUnitDays
At 2016-12-311,675,462USD
At 2015-12-311,675,462USD

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2016-01-01 to 2016-12-314,750,414USD366
2015-01-01 to 2015-12-315,158,874USD365

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2016-12-31858,140shares
At 2015-12-31858,140shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2016-12-3183,451,222USD
At 2015-12-3166,256,494USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2016-12-315,745,148USD
At 2015-12-315,674,025USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2016-12-314,301,090USD
At 2015-12-313,945,554USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2016-12-3111,872USD
At 2015-12-3111,872USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2016-12-31693,569USD
At 2015-12-31267,783USD

Net deferred tax assets

Deferred tax assets after the valuation allowance. Realization depends on future taxable income, so the balance is not a receivable from tax authorities.

PeriodValueUnitDays
At 2016-12-3153,992,692USD
At 2015-12-3150,039,461USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2016-01-01 to 2016-12-314,699,338USD366
2015-01-01 to 2015-12-313,395,360USD365

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2016-01-01 to 2016-12-31356,665USD366
2015-01-01 to 2015-12-31362,502USD365

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2016-01-01 to 2016-12-313,269,426USD366
2015-01-01 to 2015-12-313,262,835USD365

Current income tax expense or benefit

Income tax expense or benefit for the period that is currently payable or refundable. It differs from cash taxes paid and from total tax expense.

PeriodValueUnitDays
2016-01-01 to 2016-12-310USD366
2015-01-01 to 2015-12-310USD365

Deferred income tax expense or benefit

The deferred portion of income tax expense or benefit, arising from timing differences. It is not tax paid in the period.

PeriodValueUnitDays
2016-01-01 to 2016-12-31-3,953,231USD366
2015-01-01 to 2015-12-31-3,063,079USD365

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2016-01-01 to 2016-12-3112,321,313USD366
2015-01-01 to 2015-12-313,300,000USD365

Inspect the source

Entity
Cellectar Biosciences, Inc. / CIK 0001279704
Captured
2026-09-20T07:48:31.991Z
SEC response SHA-256
44da00fed89c835867d9290b98319109f07ad849957763fd081353f99891a212

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001279704.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))